In an exciting leap for stem cell research and regenerative medicine, Regenerative Orthopedics & Sports Medicine (ROSM) has joined forces with Orthobiologics Research Initiative Inc. (ORI) in a groundbreaking study funded by the Maryland Stem Cell Research Fund.
This innovative research, set for completion by December 2026, focuses on harnessing the healing potential of microfat stem cells to treat rotator cuff injuries—a prevalent orthopedic issue affecting over 2 million Americans annually.
This two-year, placebo-controlled study aims to explore non-surgical stem cell therapies as a viable solution for partial-thickness rotator cuff tears, a condition often treated with invasive procedures.
By focusing on microfat stem cells, this research could offer a powerful alternative to surgery, minimizing recovery times and making care accessible to more patients.
Importantly, this trial will prioritize underserved communities in Maryland, bringing state-of-the-art orthobiologic treatments to those most in need.
According to ROSM CEO Dr. John Ferrell, this collaboration marks “a significant step forward in orthopedic care,” with a mission to revolutionize recovery options for those living with chronic rotator cuff injuries.
To see this study through to completion, the research team is seeking an additional $360,000 in donations from the public, emphasizing community support in driving forward this pioneering work.
This partnership stands as a beacon of innovation in regenerative orthopedics, and the outcomes could reshape the future of orthopedic care, making stem cell treatments a mainstream solution for rotator cuff injuries.
For those interested in supporting this transformative work, visit rosm.org to learn more about donating and contributing to this promising medical breakthrough.